Document is current
Any future updates will be listed below
-
Authors
Nordengen, Kaja
Kirsebom, Bjørn-Eivind
Richter, Grit
Pålhaugen, Lene
Gísladóttir, Berglind
Siafarikas, Nikias
Nakling, Arne
Rongve, Arvid
Bråthen, Geir
Grøntvedt, Gøril Rolfseng
Gonzalez, Fernando
Waterloo, Knut
Sharma, Kulbhushan
Karikari, Thomas
Vromen, Eleonora M.
Tijms, Betty M.
Visser, Pieter J.
Selnes, Per
Kramberger, Milicia G.
Winblad, Bengt
Blennow, Kaj
Fladby, Tormod
-
Funding
Funding for this research was provided by:
EU Joint Programme – Neurodegenerative Disease Research
Helse Nord RHF (1540-20, 1540-20, 1540-20)
Helse Sør-Øst RHF
- License Information
-
More Information
Article History
Received: 30 June 2023
Accepted: 28 November 2023
First Online: 13 December 2023
Declarations
:
: The project has been considered by the Norwegian Regional Ethics Committee (approval number for the DDI project: 2013/150, approval number for the biobank: 2011/1051). The local data protection officer at Akershus University Hospital has also approved the study with the according approval number 13-056, 14-156 and 13-088. Data handling was in accordance with local and national regulations, with security precautions for storage and regulated biobank facilities. Both sexes are equally included, patients and controls give informed consent to participate in the study. The DDI has a patient and caregiver representative in the steering group. User participation is ensured with open meetings and written information. The study conduct was in line with the guidelines provided by the Helsinki declaration of 1964 (revised 2013) and the Norwegian Health and Research Act.
: Not applicable.
: KN has publishing royalties from the popular science books published at Kagge Forlag AS and gets honoraria for talks based on these from Athenas speakers’ bureau. BEK has served as a consultant for Biogen. TF is inventor and co-founder of Pre Diagnostics A/S, serves at advisory boards for Biogen and Novo Nordisk. PS has served as a consultant for Roche. KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. All other authors declare that they have no competing interests.
